These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 14675866)

  • 1. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
    Van Vaerenbergh K; Van Laethem K; Albert J; Boucher CA; Clotet B; Floridia M; Gerstoft J; Hejdeman B; Nielsen C; Pannecouque C; Perrin L; Pirillo MF; Ruiz L; Schmit JC; Schneider F; Schoolmeester A; Schuurman R; Stellbrink HJ; Stuyver L; Van Lunzen J; Van Remoortel B; Van Wijngaerden E; Vella S; Witvrouw M; Yerly S; De Clercq E; Destmyer J; Vandamme AM
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2109-17. PubMed ID: 10898683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.
    Quiñones-Mateu ME; Tadele M; Parera M; Mas A; Weber J; Rangel HR; Chakraborty B; Clotet B; Domingo E; Menéndez-Arias L; Martínez MA
    J Virol; 2002 Oct; 76(20):10546-52. PubMed ID: 12239335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
    Li Z; Terry B; Olds W; Protack T; Deminie C; Minassian B; Nowicka-Sans B; Sun Y; Dicker I; Hwang C; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5500-8. PubMed ID: 23979732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.
    Van Dyke RB; Wang L; Williams PL;
    J Infect Dis; 2008 Dec; 198(11):1599-608. PubMed ID: 19000014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
    Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
    J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.
    Nouhin J; Madec Y; Ngo-Giang-Huong N; Ferradini L; Nerrienet E
    PLoS One; 2013; 8(8):e73744. PubMed ID: 24015311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report of the rare deletion at codon 69 of reverse transcriptase in a South African HIV-1 subtype C infected patient.
    Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA
    Virus Genes; 2010 Dec; 41(3):358-60. PubMed ID: 20890651
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
    Bulgheroni E; Croce F; Citterio P; Viganò O; Visonà R; Sala E; Galli M; Rusconi S
    J Clin Virol; 2004 Jan; 29(1):27-32. PubMed ID: 14675866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.